David Lewis
Stock Analyst at Morgan Stanley
(2.77)
# 1,868
Out of 4,876 analysts
270
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $117 → $127 | $134.38 | -5.49% | 24 | Apr 17, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $313.08 | -4.18% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $170.86 | +60.95% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $86.33 | +5.41% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $19.07 | +3,675.56% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $30.39 | +229.06% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $131.45 | -88.59% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $2.60 | +1,053.85% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $65.01 | +15.37% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $19.67 | +128.77% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $73.80 | -18.70% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $58.60 | +39.93% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $119.47 | +260.76% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $86.02 | +79.03% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $18.43 | +117.04% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $78.21 | +72.61% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $393.55 | -28.85% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $533.71 | -46.60% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $6.77 | +180.65% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $154.71 | -39.24% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $87.81 | -10.03% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $91.46 | +96.81% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $152.41 | +22.70% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $12.21 | +268.55% | 5 | Dec 15, 2020 |
Abbott Laboratories
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $117 → $127
Current: $134.38
Upside: -5.49%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $313.08
Upside: -4.18%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $170.86
Upside: +60.95%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $86.33
Upside: +5.41%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $19.07
Upside: +3,675.56%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $30.39
Upside: +229.06%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $131.45
Upside: -88.59%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $2.60
Upside: +1,053.85%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $65.01
Upside: +15.37%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $19.67
Upside: +128.77%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $73.80
Upside: -18.70%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $58.60
Upside: +39.93%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $119.47
Upside: +260.76%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $86.02
Upside: +79.03%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $18.43
Upside: +117.04%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $78.21
Upside: +72.61%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $393.55
Upside: -28.85%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $533.71
Upside: -46.60%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $6.77
Upside: +180.65%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $154.71
Upside: -39.24%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $87.81
Upside: -10.03%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $91.46
Upside: +96.81%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $152.41
Upside: +22.70%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $12.21
Upside: +268.55%